ABVC BIOPHARMA INC (ABVC) Stock Balance Sheet
NASDAQ:ABVC • US00091F3047
Current stock price
1.14 USD
-0.04 (-3.39%)
Last:
| MRQ (2025-9-30) | 2025 (2025-12-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | N/A | N/A | |||
| Cash Equivalents | 192.10K | 681.50K | 248.40K | 60.20K | 90.00K | |||
| Marketable Securities | 65.20K | 64.40K | 64.70K | 79.30K | 80.00K | |||
| Receivables | 1.93M | 763.40K | 1.16M | 759.60K | 1.37M | |||
| Inventories | 11.50K | N/A | N/A | N/A | 0.00 | |||
| Other Current Assets | 1.11M | 992.10K | 711.60K | 757.70K | 1.46M | |||
| Total Current Assets | 3.31M | 2.50M | 2.18M | 1.66M | 2.99M | |||
| Non-Current Assets | ||||||||
| PPE Net | 13.22M | 14.75M | 1.15M | 1.38M | 1.74M | |||
| Investments And Advances | 2.75M | 1.88M | 2.26M | 2.53M | 840.00K | |||
| Goodwill | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 1.93M | 1.93M | 1.95M | 2.11M | 3.15M | |||
| Total Non-Current Assets | 17.90M | 18.56M | 5.36M | 6.13M | 6.87M | |||
| TOTAL ASSETS | 21.21M | 21.06M | 7.54M | 7.78M | 9.86M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 809.10K | 755.50K | 840.30K | 899.30K | 1.89M | |||
| Current Portion Of LT Debt. | 218.80K | 799.00K | 950.10K | 886.50K | N/A | |||
| Accrued Expenses | 3.12M | 4.01M | 3.61M | 3.52M | 3.28M | |||
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | |||
| Other Current Liabilities | 2.39M | 600.40K | 1.16M | 793.30K | 650.00K | |||
| Total Current Liabilities | 6.54M | 6.16M | 6.56M | 6.10M | 5.82M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 176.10K | 1.60M | 258.50K | 429.10K | 800.00K | |||
| Total Non-Current Liabilities | 2.61M | 3.79M | -243.70K | 128.50K | 940.00K | |||
| TOTAL LIABILITIES | 9.15M | 9.95M | 6.31M | 6.23M | 6.76M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -74.09M | -76.86M | -68.95M | -64.05M | -54.90M | |||
| Additional Paid In Capital | 93.91M | 96.01M | 78.60M | 73.98M | 67.91M | |||
| Minority Interest | 2.44M | 2.19M | -502.20K | -300.60K | 140.00K | |||
| Common Shares | 24.20K | 25.10K | 13.90K | 7.90K | 30.00K | |||
| Treasury Stock | -8.91M | -8.91M | -8.91M | -8.90M | -9.10M | |||
| Other Shareholders' Equity | 1.12M | 846.60K | 476.70K | 516.40K | -840.00K | |||
| Shares Outstanding | 24.19M | 25.05M | 13.87M | 7.94M | 3.29M | |||
| Tangible Book Value per Share | 0.50 | 0.44 | 0.09 | 0.20 | 0.94 | |||
| Total Shareholders' Equity | 12.06M | 11.11M | 1.23M | 1.55M | 3.10M | |||
| TOTAL LIABILITIES AND EQUITY | 21.21M | 21.06M | 7.54M | 7.78M | 9.86M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 0.51 | 0.41 | 0.33 | 0.27 | 0.51 | |||
| Return On Assets (ROA) | -23.16% | -37.55% | -65.03% | -100.05% | -166.53% | |||
| Return On Equity (ROE) | -40.73% | -71.17% | -399.88% | -501.13% | -529.68% | |||
All data in USD , ROIC based on taxRate of 0.21